What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025BloodOpen Access

The role of high-dose vitamin c in management of hematological malignancies: Asystematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Overall survival rates at 6, 12, 18, and 24 months were observed at 85.43%, 75.87%, 68.23%, and 59.18%, respectively.
Pooled analysis included 19 studies with 695 patients, highlighting a significant response to vitamin C as an adjunct to chemotherapy.
The evaluated chemotherapy in conjunction with high-dose vitamin C suggests enhanced progression-free survival for hematological malignancies.
Results underscore the importance of high-dose vitamin C in treatment regimens, necessitating further trials for validation.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Meta-analysis shows improved survival rates in patients with hematological malignancies receiving vitamin C with chemotherapy, suggesting beneficial adjunct therapy.

Cite This Study

Sattar et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d430 https://doi.org/10.1182/blood-2025-8116

View Full Paper

Ask AI

Bookmark

Implication

Meta-analysis shows improved survival rates in patients with hematological malignancies receiving vitamin C with chemotherapy, suggesting beneficial adjunct therapy.

The role of high-dose vitamin c in management of hematological malignancies: Asystematic review and meta-analysis

Key Points

Discussion

Implication

Cite This Study

The role of high-dose vitamin c in management of hematological malignancies: Asystematic review and meta-analysis

Key Points

Discussion

Implication

Cite This Study